Brexit? The impact on health policy and pharmaceuticals

The bill providing for a referendum on UK membership of the European Union is now before the UK House of Commons. The referendum will be held before the end of 2017. A British exit from the European Union would have a profound impact on British and EU health policies as well as on pharmaceutical regulation (one of the longest standing harmonised sectors) and on pharmaceutical companies operating in Europe.

This panel discussion will explore the impact of a potential 'Brexit' for the EU, UK, Industry, life sciences and patients.


Andrew Hollingsworth - Former Policy Manager, ABPI and Cancer Research UK

Elizabeth Kuiper - Director European Affairs, EFPIA

Nina Renshaw - Secretary General, EPHA

Ian Schofield - Analyst, Scrip Intelligence


To RSVP, email


July 02, 2015 at 12:30pm - 2:30pm
37 Square de Meeus
Brussels 1000
Google map and directions

Be the first to comment

Please check your e-mail for a link to activate your account.